论文部分内容阅读
目的 :探讨P16蛋白在卵巢上皮性肿瘤中的表达及临床意义。方法 :采用SP免疫组化法检测P16蛋白在 82例卵巢上皮性肿瘤组织 (良性 2 0例 ,恶性癌 6 2例 )及 1 5例正常卵巢组织常规石蜡标本的表达。结果 :P16蛋白在卵巢上皮性癌中检出率为 5 3 2 % ,低于良性卵巢瘤 90 0 %及正常组织 93 3% (P <0 0 1 )。不同分化程度卵巢癌之间P16蛋白的阳性率无显著差别 (P >0 0 5 ) ,P16蛋白表达与临床分期及预后有关 (P <0 0 5 ,P <0 0 1 )。结论 :P16蛋白在卵巢上皮性恶性肿瘤的发生、发展中起作用 ,P16的缺失表达与卵巢癌的进展和预后不良有关。
Objective: To investigate the expression and clinical significance of P16 protein in epithelial ovarian tumors. Methods : SP immunohistochemical method was used to detect the expression of P16 protein in 82 cases of ovarian epithelial tumor (benign in 20 cases, malignant carcinoma in 62 cases) and 15 cases of normal paraffin tissue. Results: The detection rate of P16 protein in epithelial ovarian cancer was 532%, which was lower than that of benign ovarian tumor (90.0%) and normal tissue (93%) (P < 0.01). There was no significant difference in the positive rate of P16 protein among ovarian cancers with different degree of differentiation (P > 0.05), and the expression of P16 protein was correlated with clinical stage and prognosis (P <0 05, P <0 01). Conclusion : P16 plays a role in the occurrence and development of ovarian epithelial malignant tumors. The lack of P16 expression is related to the progression of ovarian cancer and poor prognosis.